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SHORT COMMUNICATION
High-dose interleukin 2 promotes bacterial translocation from the gut
JV Reynolds'. P Murchan'. N Leonard, DB Gough,f P Clarke4, FBV Keane' and WA Tanner5
.Department ofl Surgery. St. James University Hospital, Leeds LS9 7TF, UK: 2Department of Pathology, St. James Hospital,
Dublin 2, Ireland: 'Department of Surgery, Beaumount Hospital, Dublin 7, Ireland: 'Department ofMicrobiology, Royal College
ofSurgeons in Ireland, Dublin 2. Ireland: "Department ofSurgern, Meath Hospital, Dublin 8, Ireland.
Summarv Toxicitv associated with high-dose recombinant interleukin 2 (rIL-2) therapy simulates a sepsis
svndrome. but the mechanism remains unclear. We hvpothesised that translocated gut-origin bacteria may be
important. Fifty-one male rats A-ere randomised to receive rIL-2 by intraperitoneal injection at doses (IU) of
1IW (n = 15). 104 (n = 8). 1iO (n = 8) or 102 (n = 8) twice daily. or a saline bolus (n = 12). After 5 days. ileal
histomorpholog- was assessed and the mesenteric lymph node complex cultured. Results showed that
colomisation of mesenteric lymph nodes with Escherichia coli occurred in all rats treated with I0W IU of rIL-2.
and in 620o. 37`o and 12o/ of rats treated with decreasing doses of rIL-2. No translocation was observed in
control animals. An increase in submucosal lymphatics and occasional mucosal disruption was seen onlv in the
group receiving IW; IU. These data show that rIL-2 promotes bacterial translocation and suggests a
mecham'sm that may fuel high-dose rIL-2 toxicity in man.
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The gene for human interleukin 2 was cloned in 1983
(Taniguchi et al.. 1983). enabling production of abundant
quantities of recombinant interleukin 2 (rIL-2). With remark-
able success in experimental models. high-dose rIL-2. either
alone or in combination with lymphokine-activated killer
cells. tumour-infiltrating lymphocytes or other cytokines. has
subsequently undergone widespread clinical evaluation. Alth-
ough impressive responses are observed. particularly in
metastatic melanoma and renal cell carcinoma (Rosenberg.
1992). substantial toxicity. sometimes life-threatening, has
lessened its widespread appeal (Siegel and Pun. 1991). While
many groups are evolving to a new era of adoptive
immunotherapy using gene-modified tumour or lymphoid
cells in combination with rIL-2 (Rosenberg. 1992; Crowley
and Seigler. 1993), it is unfortunate that at the end of its first
decade we are not much wiser about the mechanism of rIL-2
toxicity or its potential modulation.
The pathophysiology of rIL-2-miduced toxicity is asso-
ciated with increased membrane permeability that leads to
fluid and protein losses into visceral and soft tissues (Rosen-
thein et al.. 1986). a so-called vascular leak syndrome. High-
dose rIL-2 administration is associated with decreased
systemic vascular resistance, an increase in cardiac index.
neutrophil leucocytosis. raised serum adrenocorticotrophic
hormone and elevated serum levels of tumour necrosis factor
alpha (TNF-a) interleukin I (IL-1). and gamma-interferon
(IFN-y) (Siegel and Puri. 1991). The metabolic, physiological.
immunological and endocrinological changes induced by
rIL-2 closely simulate the septic state. particularly Gram-
negative sepsis with endotoxaemia (Hack et al.. 1991). The
gastrointestinal tract has been identified as an occult source
of sepsis in many cnrtically ill patients (Goris et al., 1985:
Deitch. 1992). Bacterial translocation. the passage of bacteria
from an intact gastrointestinal tract to normally sterile tissues
such as the mesenteric lymph nodes and liver, is central to
this theory of gut-origin sepsis. The effects of rIL-2 on this
phenomenon have not been descnrbed: the focus of this study
was to address if some of the toxicitv of high-dose rIL-2
therapy could relate to translocation of Gram-negative
bacteria.
Materials and methods
Experimental groups andprotocol
Fifty-one male Sprague-Dawley rats weighing 200-250 g
were studied. Endotoxin-free human recombinant interleukin
2 (Eurocetus. The Netherlands) was used. There were five
treatment groups: group A (n = 15). rIL-2. 10' IU twice daily
(b.d.) by intraperitoneal (i.p.) injection in 0.4 cm of saline:
group B (n = 8). rIL-2. 104 IU b.d.; group C (n = 8). rIL-2,
103 IU b.d.; group D (n = 8). rIL-2, 102 IU b.d.: and group E
(n = 12). saline alone. 0.4 cm3 i.p. b.d.
All animals received a total of ten injections over 5 days.
They were then sacrificed by cervical dislocation. The ileum
was excised for routine light microscopy. The mesentenrc
lymph node (MLN) complex was carefully excised for
bacteriological studies.
Microbiological assays
The MLN complex was homogenised in Ringer's solution.
and plated at multiple dilutions on McConkey agar and on
blood agar. Plates were cultured for 48 h under aerobic
(McConkey and blood agar) and anaerobic (blood agar)
conditions. MLN colonisation is expressed as the number of
colony-forming units (c.f.u.) per ml of homogenate. Colony-
forming units were counted to an arbitrarv maximum of 105.
Statistical analysis
Statistical significance was computed using the Mann-
Whitney U-test.
Results
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There was no mortality in any group. There was no sig-
nigicant difference in body weight changes between groups
Escherichia coli was the sole organism isolated in all but twc
colonised nodes, these containing in addition Proteus mirab-rJL-2pRynos eal trascation
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ilis and Streptococcus faecalis. The incidence of E. coli col-
onisation of mesenteric nodes and the mean c.f.u. per ml of
cultured nodes is shown in TableI. No saline-treated rat had
evidence of bacterial colonisation of the MLN complex. For
rIL-2-treated groups, there was a dose-dependent increase in
colonised nodes, with all rats in the group receiving the
highest dose of rIL-2 havingE. coli colonisation of the MLN
complex. This was significantly (P<0.001) greater thanin all
other groups. Furthermore, intense colonisation of nodes was
observed only in this group with consistent yields of > I0f
c.f.u. per ml of homogenate. Nodal yields ofE. coli in other
groups varied from 5 to l03 c.f.u. ml-1.
Histopathological changes in villus architecture were
observed only in rats receiving 1IW IU of rIL-2. A marked
increase in submucosal vessels, most probably lymphatics,
was observed in all rats in this group. Four rats in this group
had in addition evidence of mucosal disruption with loss of
epithelial cells (Figure 1).
Discussion
The theory that translocation of bacteria and endotoxin from
the gastrointestinal tract may initiate or exacerbate septic
states is increasingly accepted (Van Leeuwen et al.. 1994). In
this so-called gut hipothesis of sepsis and multiple organ
failure. translocated enteric bacteria and endotoxin induce
cytokine secretion from tissue macrophages. stimulate neut-
rophil responses and promote a proinflammatory endothelial
cell phenotype: organ injury may be mediated by complement
and coagulation system activation as well as the products of
activated phagocytes and neutrophils, including reactive
oxygen intermediates. cytokines and proteases (Deitch. 1992).
This theory may explain why no septic focus is identified in
approximately 30% of bacteraemic patients dying of sepsis
(Goris et al.. 1985). Furthermore, gut-derived bacteria or
endotoxin may fuel this immunoinflammatory septic state in
the absence of microbiological evidence of infection.
Table 1 Incidence of E. col colomnsation of the MLN complex and
median c.f.u. ml- ' per colonised complex in each group
rIL-2 Incidencee
Group UI) no. total (0nv fedian (range,v cfu. ml- '
A 10- 1515(100) > I0 (>0- all rats)
B 104 5 8 (62) 600 (5-0I )
C 10 3 8( 37) 20(10-60)
D 10' 1 8( 12) 15 (15)
E - 0121 0) -
aGroup A is significantly different (P <0.001) from all other treatment
groups with respect to incidence ofMLN colonisation and median c.f.u.
ml-'. P<0.0001 group A vs E for both these parameters.
_ t s -F a~
Figure 1 High-power ( x 25) photomicrograph of villi from rat
receiving 105 IU of rIL-2 b.d. showing dilated lymphatics and
mucosal disruption with loss of epithelial cells.
Experimental studies have shown that the mesenteric
lymph node is the most reliable site to culture for the pur-
poses of monitoring bacterial translocation. Our experimental
design focused on this parameter and clearly shows a dose-
dependent increase in bacterial translocation with rIL-2
administration. All colonised lymph nodes contained E. coli
and hence endotoxin. Although rIL-2 at concentrations of
10' IU-104 IU b.d. produced translocation, the bacterial
yield per ml of homogenised nodes was markedly less than in
the group of 15 rats who received 10 IU b.d.. all of which
grew more than 100000 E coli c.f.u. ml-'.
The mechanism of rIL-2-induced translocation is unk-
nown. Usually one or more conditions are necessary for
bacterial translocation to occur (Wilmore et al., 1988): (1)
physical disruption of the mucosal barrier; (2) altered
ecological balance of the gastrointestinal flora, most usually
with Gram-negative overgrowth: and (3) impaired immune
defences. Mucosal disruption was observed using light mic-
roscopy in 4 of 15 rats receiving high-dose rIL-2. and all rats
in this group had dilated submucosal vessels, probably lym-
phatics. There was no eVidence of substantially increased
tissue oedema. suggesting that increased microvascular
permeability in the gut is unlikely to be a significant compo-
nent. We are currently evaluating flora and assessing immune
function in these groups. We do not know if high-dose rIL-2
promotes bacterial translocation via a direct action on the
gastrointestinal tract or secondary to gut microcirculatory or
inflammatory changes consequent on the generation of sub-
stantial local proinflammatory cytokines and other
mediators. For neutrophils to mediate injury, adhesion to
endothelial cells is a prerequisite. In man the intercellular
adhesion molecule 1 (ICAM-1). the ligand for CDlla, is
induced de novo in skin biopsies of patients treated with
high-dose rIL-2 (Cotran et al.. 1987). High-dose rIL-2
induces TNF-a and IFN-y. which contribute to the toxic
effects of rIL-2 (Economou et al.. 1991). Furthermore, other
experimental studies have correlated tissue injury induced by
rIL-2 with raised levels of the proinflammatory mediators
thromboxane B2 (Welbourn et al.. 1991) and leukotriene B4
(Klausner et al.. 1990). Since rIL-2 does not produce in-
creased vascular permeability in nude mice, it is very likely
that indirect or secondary events with gastrointestinal or
systemic immune cells are of greatest importance. Irrespective
of the mechanism of translocation, once bacterial and
endotoxin translocation is initiated, a self-perpetuating cycle
of translocation may be sustained, because E. coli endotoxin
is itself a potent promoter of translocation (Deitch, 1992).
Do these data have clinical relevance? Although E. coli
bacteraemia is well described. the most common organisms
causing nosocomial bacteraemia in patients on high-dose
rIL-2 are Staphylococcus aureus and Staphylococcus epidermis
(Snydman et al.. 1990). Gastrointestinal side-effects are, how-
ever. extremely common in patients receiving high-dose rIL-
2. occurring in 85% of patients. and intestinal necrosis and
perforation have been described (Rahman et al.. 1991). We
suggest that translocation may fuel toxicity in man without
producing microbiological evidence of infection. Most
patients with rIL-2 toxicity have features of sepsis. despite
negative systemic cultures: E. coli and endotoxin may
activate the host neutrophils and phagocytes to produce the
immunoinflammatory mediators responsible for the sepsis
syndrome. The hepatic mononuclear phagocyte, the Kuppfer
cell. may be a key regulatory player. contributing to the
manifestations of sepsis through cytokine elaboration and
limiting the passage of E. coli and endotoxin from the portal
to the systemic circulation.
In conclusion, we have observed for the first time that
high-dose rIL-2 produces bacterial translocation in rats.
These observations may enable us to evaluate strategies
directed at decreasing toxicity of high-dose rIL-2, either by
decreasing bacterial and endotoxin translocation or limiting
the consequences of endotoxaemia. Selective gut decon-
tamination. early enteral nutrition. glutamine supplementa-
tion. polymyxin B. anti-endotoxin and anti-TNF antibodies
have theoretical rationale (Deitch. 1992).
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